IP Library › Granted Patent US 10,273,211
Granted Patent B2
US 10,273,211 · App. 14/776,337 · Granted Apr 30, 2019

Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Inventors: Dana T. Aftab (San Rafael, CA); Sriram Naganathan (San Jose, CA); Wei Xu (Danville, CA); Steven Lacy (San Mateo, CA); Linh Nguyen (San Francisco, CA)
Assignee: Exelixis, Inc.
C07D215/22C07C233/60C07C305/24C07D215/60G01N33/487C07C2601/02G01N2570/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,273,211
App. No.
14/776,337
Granted
Apr 30, 2019
Kind
B2
Abstract

The invention relates to metabolites of cabozantinib (I) as well as uses thereof.

Claims (3)

1. A pharmaceutical composition comprising a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.

2. The composition of claim 1 , which is suitable for oral administration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2015
From: NAGANATHAN, SRIRAM; AFTAB, DANA T.; XU, WEI; NGUYEN, LINH; LACY, STEVEN
To: EXELIXIS, INC.
Reel/Frame 036565/0727 →
Continuity (2)
Provisional Application 61792413 · Mar 15, 2013
Related Publication 20160031818A1 · Feb 4, 2016
Cited By (6)
US 12,415,784 US 12,486,233 US 12,516,025 US 12,516,026 US 12,522,567 US 12,552,749